Department of Rheumatology, INSERM U831-Université de Lyon, Hôpital Edouard Herriot, Hospices Civils de Lyon, Lyon 69003, France.
Osteoporos Int. 2011 Apr;22(4):1023-36. doi: 10.1007/s00198-010-1462-4. Epub 2010 Oct 20.
Inflammatory joint diseases are responsible of chronic systemic inflammation, joint degradations, deformities, and altered quality of life. Patients suffering from chronic rheumatic diseases also present increased bone fragility and increased fracture risk. Registration of biologic therapies has deeply modified care in rheumatic diseases, especially in rheumatoid arthritis and ankylosing spondylitis. The available biologics are the anti proinflammatory cytokine therapies (TNFα blockers, anakinra and tocilizumab) and the biologics active on T cell activation (abatacept and rituximab). These drugs succeeded in blocking disease activity and joint degradation. They are also able to stop systemic bone loss among patients with inflammatory rheumatic diseases. In this review, we present the current understanding of the inflammatory-induced bone loss and the skeletal effects of biologic therapies in inflammatory joint diseases.
炎症性关节疾病可导致慢性全身炎症、关节退化、畸形和生活质量下降。患有慢性风湿性疾病的患者还存在骨脆性增加和骨折风险增加。生物制剂的注册极大地改变了风湿性疾病的治疗，特别是类风湿关节炎和强直性脊柱炎的治疗。现有的生物制剂包括抗炎细胞因子治疗（TNFα 阻滞剂、阿那白滞素和托珠单抗）和针对 T 细胞活化的生物制剂（阿巴西普和利妥昔单抗）。这些药物成功地阻断了疾病活动和关节退化。它们还能够阻止炎症性风湿性疾病患者的全身骨质流失。在这篇综述中，我们介绍了炎症引起的骨质流失的最新认识，以及生物制剂在炎症性关节疾病中的骨骼作用。
